Published Date:2021-01-29
Original Link:https://www.onenessbio.com/en/news_detail23_4.htm
| No | 1 | Date of announcement | 2021/01/29 | Time of announcement | 18:54:40 |
|---|---|---|---|---|---|
| Subject | Oneness Biotech Co.,LTD receives a European patent on antagonistic CTLA-4 aptamers. | ||||
| To which item it meets |
paragraph 53 | Date of events | 2021/01/29 |
||
| Statement | |||||
|
1.Date of occurrence of the event:2021/01/29
2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:The Company has been informed by the patent agency that the antagonistic CTLA-4 aptamer has been granted a European patent titled ”ANTAGONISTIC CTLA-4 APTAMERS AND APPLICATIONS THEREOF IN ENHANCING IMMUNE ACTIVITY” under patent number 3174984. 6.Countermeasures:None 7.Any other matters that need to be specified: (1)This patent covers a group of aptamer sequences that bind and inhibit cytotoxic T-lymphocyte associated protein 4 (CTLA-4) to enhance immune activities. These aptamers can be developed as cancer drugs to treat lungcancer, melanoma, colorectal cancer or renal-cell cancer. (2)This patent is owned by National Taiwan University, Taipei Medical University and Academia Sinica. Oneness Biotech Co.,LTD has been exclusively authorized to use this patent and to manufacture, use and sell the products of this invention. |
|||||